Kenvue (KVUE) Q3 sales rise 3.2%, but skin and beauty weakness complicates Kimberly-Clark merger outlook

Kenvue Inc. (NYSE: KVUE) reported third-quarter 2026 revenue growth of 3.2% to approximately $3.89 billion on October 30, supported by stronger demand in its Self Care and Essential Health businesses. Organic sales increased 2.9%, operating margin improved to 18.2% from 16.7%, and reported diluted earnings per share rose to $0.22 from $0.21. However, Skin Health and Beauty organic sales declined 0.5%, with lower product volumes offsetting improved pricing and growth within selected haircare brands. The results arrive as Kenvue prepares for its pending acquisition by Kimberly-Clark Corporation, creating an important test of whether the consumer health group’s improving margins and cash generation can translate into sustainable value after the combination.

Why did Kenvue’s third-quarter sales increase 3.2% while its Skin Health and Beauty business remained weak?

Kenvue reported quarterly net sales of $3.886 billion, compared with $3.764 billion in the corresponding period of 2025. The 3.2% improvement reflected 2.9% organic sales growth and a 0.3% favourable currency contribution. Organic growth included a 1.6% increase in volume and a 1.3% improvement in value realisation, indicating that both additional products sold and pricing contributed to the result.

The performance marked Kenvue’s fourth consecutive quarter of net and organic sales growth. This suggests that the company’s operating recovery is becoming more consistent, although the rate of improvement remains uneven across its portfolio. Self Care and Essential Health provided the main sources of expansion.

Skin Health and Beauty reported net sales of $1.039 billion, virtually unchanged from $1.038 billion a year earlier. Reported growth was just 0.1%, while organic sales declined 0.5%. The small reported increase reflected a favourable currency contribution that offset weaker underlying demand.

The segment’s organic sales decline was driven by a 1.7% reduction in volume, partly offset by 1.2% favourable value realisation. Management identified distribution losses and promotional timing in the United States, alongside retailer negotiations in Europe, as factors affecting performance. These explanations indicate that commercial execution and retail distribution contributed to the weakness rather than providing evidence of a uniform decline in consumer interest across every beauty brand.

The contrast between positive group growth and negative beauty volumes is commercially important. Skincare and personal care products operate in highly competitive categories where shelf placement, retailer promotions and product innovation influence purchasing decisions. Even established brands can experience volume pressure when distribution changes or consumers shift towards competing products.

The results suggest that Kenvue’s recovery is being supported primarily by categories outside its skin and beauty portfolio. Restoring more consistent demand in those products would provide an additional source of growth and improve the balance of the company’s earnings base ahead of the Kimberly-Clark combination.

How are Neutrogena, Rogaine and OGX influencing Kenvue’s beauty and personal care strategy?

Kenvue reported low-double-digit organic sales growth in Hair Care during the third quarter. Rogaine achieved its fourth consecutive quarter of market-share gains, while OGX continued benefiting from product development and commercial activity. The performance indicates that selected brands are generating stronger demand even while the wider Skin Health and Beauty segment remains under pressure.

The divergence reflects the different consumer needs addressed within the portfolio. Haircare products compete through performance, formulation, brand credibility and increasingly specialised consumer preferences. Products associated with hair growth or targeted treatment can occupy different purchasing categories from mainstream skincare and bodycare offerings.

Kenvue has also continued investing in Neutrogena, including the launch of Neutrogena Cloud Tech featuring bemotrizinol, also known as BEMT, within its North American sun-care offering. The company identified the product and the continued expansion of Neutrogena Ultra Sheer Sun as contributors to innovation activity. These launches are intended to strengthen product relevance and distribution, although the latest results do not disclose enough information to calculate their individual sales contributions.

The use of new formulation technologies can help differentiate sunscreen products in a competitive market. However, the commercial benefit depends on consumer adoption, pricing, retailer support and the evidence supporting product claims. Product innovation does not automatically produce higher category profitability if increased development and marketing costs absorb the associated revenue.

The OGX ProGrowth and ProGrowth + Peptide platforms also contributed to the company’s innovation programme. Kenvue’s continued investment in targeted product development suggests that management is attempting to strengthen growth through differentiated formulations rather than relying solely on price increases. The effectiveness of that approach will become clearer through subsequent sales volumes and market-share performance.

The latest results do not establish that Neutrogena or Aveeno individually experienced the same organic sales decline as the wider segment. The reported weakness applies to the aggregate Skin Health and Beauty business, which contains products with different growth trajectories. Any assessment of individual brand performance must therefore remain within the limits of the available disclosures.

The challenge for Kenvue is to extend the strength observed in haircare across other parts of the beauty portfolio. Better distribution, sustained innovation and more effective promotional execution could support that effort, but improvements must become visible in underlying volumes rather than currency-assisted reported sales.

Why are Tylenol, Nicorette and Essential Health brands supporting Kenvue’s operating recovery?

Kenvue’s Self Care business generated third-quarter revenue of $1.656 billion, compared with $1.564 billion a year earlier. Reported sales increased 5.9%, while organic sales rose 5.4%. The organic improvement comprised 3.4% volume growth and 2% favourable value realisation, providing evidence of both stronger consumption and pricing performance.

Management identified several contributors to the improvement. Nicorette delivered low-double-digit organic sales growth, supported by demand in Europe, the Middle East, Africa and Asia Pacific. Pepcid continued outperforming its category, while Motrin benefited from innovation and commercial activity in markets experiencing increased seasonal illness.

Tylenol also gained market share in the United States, despite category softness and lower seasonal incidence compared with the previous year. Kenvue described improving US consumption trends during the quarter. The market-share gains indicate relative competitive progress, although they do not necessarily mean that the overall category experienced substantial demand growth.

Essential Health reported revenue of $1.191 billion, an increase of 2.5% from $1.162 billion. Organic sales also increased 2.5%, supported by 2% volume growth and 0.5% favourable value realisation. The category delivered growth across all geographic regions.

Johnson’s Baby contributed to the improvement through product innovation, customer engagement and social commerce activity. Women’s Health brands also supported performance, including Stayfree in India and o.b. in Europe, the Middle East and Africa. Wound Care continued benefiting from product innovation and distribution, including the expansion of BAND-AID Brand PRO HEAL 5 Day Protect.

The breadth of these products gives Kenvue exposure to different consumer needs and purchasing occasions. Some categories are influenced by seasonal illness, while others are linked to routine personal care and household demand. This diversification can moderate the impact of weakness in individual products, although it does not eliminate promotional or competitive pressures.

For the forthcoming Kimberly-Clark combination, the operating performance of these established brands provides an important financial foundation. Their recurring consumer demand and distribution networks could support the scale of the combined business, but the eventual integration benefits will depend on operational execution and the final financial structure.

How did Kenvue improve margins and free cash flow while continuing its restructuring programme?

Kenvue reported gross profit margin of 59.5% in the third quarter, compared with 59.1% a year earlier. Adjusted gross margin increased to 61.5% from 61.2%. Management attributed the improvement to supply-chain productivity, tariff refunds and favourable value realisation, partly offset by inflation and foreign-exchange effects.

Operating margin increased to 18.2% from 16.7%, representing an improvement of 150 basis points. Adjusted operating margin rose to 21.9% from 21.5%. The difference between reported and adjusted measures reflects items excluded under the company’s non-GAAP definitions, including certain restructuring and other specified expenses.

The operating improvement was supported by cost optimisation programmes, including Our Vue Forward and the 2026 Restructuring Initiative. Kenvue approved the latter programme in February 2026 to simplify its operating model, optimise supply-chain arrangements and improve organisational efficiency. Management expects approximately $250 million in pretax restructuring expenses and other charges during fiscal 2026.

These expenses represent the cost of implementing changes intended to improve future productivity. Their financial attractiveness depends on whether recurring savings exceed implementation costs and whether service, product availability and brand investment remain effective. Kenvue has reported positive margin developments, although some benefits also came from factors such as tariff refunds that may not recur consistently.

Cash generation improved significantly during the first nine months of the year. Operating cash flow increased to approximately $1.9 billion from $1.3 billion, while free cash flow rose to $1.6 billion from $1 billion. The improvement reflected higher net income and a reduction in working-capital requirements.

Capital expenditure declined to approximately $300 million from $400 million during the nine-month period. Lower investment spending contributed to stronger free cash flow, although future capital requirements will depend on the company’s operating plans and the needs of the combined business after the acquisition.

Kenvue reported approximately $1 billion in cash and cash equivalents at September 27, compared with $1.1 billion at the end of December 2025. Total debt declined to $8.2 billion from $8.5 billion. The balance sheet remains relevant to the pending acquisition because the financial structure of the enlarged group will influence future interest costs and capital allocation.

What does the pending Kimberly-Clark acquisition mean for Kenvue’s consumer health and beauty portfolio?

Kimberly-Clark Corporation announced its agreement to acquire Kenvue in November 2025 through a cash-and-stock transaction. The original announcement valued Kenvue at an enterprise value of approximately $48.7 billion based on Kimberly-Clark’s share price at the time. That historical valuation should not be treated as a fixed current value because the transaction includes share consideration whose market value changes.

Under the agreement, Kenvue shareholders are entitled to receive $3.50 in cash and 0.14625 Kimberly-Clark shares for each Kenvue share, subject to the merger terms. The fixed share exchange ratio means that the value of the stock consideration varies with Kimberly-Clark’s share price. The final economic value to shareholders therefore cannot be determined solely from the original headline transaction valuation.

The combination would bring together Kimberly-Clark’s personal care and hygiene portfolio with Kenvue’s consumer health, skincare and other household care products. The businesses serve overlapping retail channels and consumer purchasing occasions, creating potential opportunities in procurement, distribution and commercial operations. However, the financial benefits depend on whether the companies can integrate effectively without weakening brand investment or customer relationships.

Kimberly-Clark originally identified expected annual run-rate synergies of approximately $2.1 billion, net of reinvestment. The target represents management’s anticipated benefits from combining the businesses rather than savings already realised. The company also indicated that achieving the synergies would involve substantial integration expenditure during the initial years following completion.

Both companies obtained shareholder approval for the transaction in January 2026, while the applicable US Hart-Scott-Rodino antitrust waiting period expired in February. The acquisition nevertheless remained pending as of October 30, with foreign regulatory approvals and other customary closing conditions still relevant. Management expects completion during the fourth quarter of 2026.

Kenvue did not provide new standalone forward-looking financial guidance with its third-quarter results because of the pending acquisition. The company also cancelled the usual quarterly earnings conference call. This makes its published financial statements especially important for assessing operating performance before the transaction closes.

The strategic value of the combination will depend partly on the condition of Kenvue’s beauty portfolio. The strongest consumer brands may benefit from greater distribution capabilities and investment resources, but weaker categories could still require product innovation and commercial improvement. Integration alone cannot be assumed to reverse negative organic sales volumes.

Why did Kenvue shares decline after the earnings announcement despite higher revenue and margins?

Kenvue shares closed at $19.31 on October 30, down approximately 1.3% from the previous session’s $19.56 closing price. Trading volume reached approximately 66.6 million shares, considerably above the roughly 12.3 million shares traded on October 29. The increase in market activity coincided with the quarterly results and continued attention around the pending Kimberly-Clark acquisition.

The stock remained close to the upper end of its 52-week trading range of approximately $14.02 to $20.13. This indicates that the share price had recovered substantially from its lower levels, although the latest trading session demonstrated that investor expectations remained sensitive to new information.

Kenvue’s valuation is influenced by the pending acquisition as well as its standalone operating performance. Because the transaction provides both cash and Kimberly-Clark shares, the changing price of the acquiring company’s stock can influence the economic value of the merger consideration. A decline in Kenvue’s share price therefore cannot be explained exclusively through its latest earnings.

The third-quarter results were positive in several important respects. Revenue growth, operating margin improvement and stronger cash generation suggest that the company’s restructuring and commercial initiatives are supporting financial performance. At the same time, continued weakness in Skin Health and Beauty indicates that important areas of the portfolio still require improvement.

The earnings results also demonstrate the challenges of evaluating a company approaching a major ownership change. Investors must assess the financial performance of Kenvue’s existing businesses while also considering the final merger consideration, regulatory completion and the prospects of the combined company. These variables can influence valuation differently.

For the operating business, the next meaningful evidence will involve continued organic volume growth, sustained margins and a recovery in Skin Health and Beauty. For the acquisition, the decisive milestones will be remaining regulatory approvals and completion of the transaction. Stronger beauty demand and successful integration would support the strategic rationale, while persistent volume weakness or higher integration costs could reduce the anticipated benefits.

Kenvue enters the proposed combination with improving cash generation and stronger performance across several consumer health categories. The commercial test for Kimberly-Clark will be whether those improvements can be preserved while restoring growth in weaker beauty businesses and delivering the operational savings expected from the merger.

What should investors know about Kenvue’s Q3 results, beauty sales decline and Kimberly-Clark merger?

• Kenvue reported third-quarter revenue of $3.886 billion, representing growth of approximately 3.2%.
• Organic sales increased 2.9%, supported by higher volume and favourable value realisation.
• Self Care organic sales rose 5.4%, while Essential Health organic sales increased 2.5%.
• Skin Health and Beauty organic sales declined 0.5%, with product volumes falling 1.7%.
• Rogaine and OGX supported haircare growth, while Neutrogena continued its product innovation programme.
• Reported operating margin improved to 18.2%, while adjusted operating margin reached 21.9%.
• Free cash flow increased to $1.6 billion during the first nine months of 2026, compared with $1 billion a year earlier.
• Kenvue ended September with approximately $1 billion in cash and $8.2 billion in debt.
• The Kimberly-Clark acquisition remained pending, with completion expected during the fourth quarter of 2026.
• KVUE closed at $19.31 on October 30, while the merger consideration remained sensitive to Kimberly-Clark’s share price and final transaction completion.